Suppr超能文献

黄酮类、非黄酮类多酚与硼替佐米协同抗多发性骨髓瘤作用

Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.

机构信息

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.

出版信息

Biomolecules. 2022 Nov 7;12(11):1647. doi: 10.3390/biom12111647.

Abstract

Multiple myeloma (MM) is a clonal plasma cell tumor originating from a post-mitotic lymphoid B-cell lineage. Bortezomib(BTZ), a first-generation protease inhibitor, has increased overall survival, progression-free survival, and remission rates in patients with MM since its clinical approval in 2003. However, the use of BTZ is challenged by the malignant features of MM and drug resistance. Polyphenols, classified into flavonoid and non-flavonoid polyphenols, have potential health-promoting activities, including anti-cancer. Previous preclinical studies have demonstrated the anti-MM potential of some dietary polyphenols. Therefore, these dietary polyphenols have the potential to be alternative therapies in anti-MM treatment regimens. This systematic review examines the synergistic effects of flavonoids and non-flavonoid polyphenols on the anti-MM impacts of BTZ. Preclinical studies on flavonoids and non-flavonoid polyphenols-BTZ synergism in MM were collected from PubMed, Web of Science, and Embase published between 2008 and 2020. 19 valid preclinical studies (Published from 2008 to 2020) were included in this systematic review. These studies demonstrated that eight flavonoids (icariin, icariside II, (-)-epigallocatechin-3-gallate, scutellarein, wogonin, morin, formononetin, daidzin), one plant extract rich in flavonoids (Punica granatum juice) and four non-flavonoid polyphenols (silibinin, resveratrol, curcumin, caffeic acid) synergistically enhanced the anti-MM effect of BTZ. These synergistic effects are mediated through the regulation of cellular signaling pathways associated with proliferation, apoptosis, and drug resistance. Given the above, flavonoids and non-flavonoid polyphenols can benefit MM patients by overcoming the challenges faced in BTZ treatment. Despite the positive nature of this preclinical evidence, some additional investigations are still needed before proceeding with clinical studies. For this purpose, we conclude by providing some suggestions for future research directions.

摘要

多发性骨髓瘤(MM)是一种起源于有丝分裂后淋巴 B 细胞谱系的克隆浆细胞瘤。硼替佐米(BTZ)是第一代蛋白酶抑制剂,自 2003 年临床批准以来,提高了 MM 患者的总生存率、无进展生存率和缓解率。然而,BTZ 的使用受到 MM 的恶性特征和耐药性的挑战。多酚分为类黄酮和非类黄酮多酚,具有潜在的促进健康的作用,包括抗癌作用。先前的临床前研究表明,一些膳食多酚具有抗 MM 的潜力。因此,这些膳食多酚有可能成为抗 MM 治疗方案中的替代疗法。本系统评价研究了类黄酮和非类黄酮多酚与 BTZ 抗 MM 作用的协同作用。从 2008 年至 2020 年在 PubMed、Web of Science 和 Embase 上收集了关于 MM 中类黄酮和非类黄酮多酚-BTZ 协同作用的临床前研究。本系统评价纳入了 19 项有效的临床前研究(发表于 2008 年至 2020 年)。这些研究表明,八种类黄酮(淫羊藿素、淫羊藿次苷 II、(-)-表没食子儿茶素-3-没食子酸酯、野黄芩素、汉黄芩素、桑色素、芒柄花素、大豆苷)、一种富含类黄酮的植物提取物(石榴汁)和四种非类黄酮多酚(水飞蓟素、白藜芦醇、姜黄素、咖啡酸)协同增强了 BTZ 的抗 MM 作用。这些协同作用是通过调节与增殖、凋亡和耐药性相关的细胞信号通路来介导的。鉴于上述情况,类黄酮和非类黄酮多酚可以通过克服 BTZ 治疗中面临的挑战使 MM 患者受益。尽管有上述临床前证据的积极性质,但在进行临床研究之前,仍需要进行一些额外的调查。为此,我们通过为未来的研究方向提供一些建议来总结。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e92/9687375/3ab28f866596/biomolecules-12-01647-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验